Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes

Antonio Canosa¹,²,³ · Andrea Calvo¹,²,⁴ · Cristina Moglia¹,² · Rosario Vasta¹ · Francesca Palumbo¹ · Luca Solero¹ · Francesca Di Pede¹ · Sara Cabras¹ · Vincenzo Arena⁵ · Grazia Zocco¹ · Federico Casale¹ · Maura Brunetti⁶ · Luca Sbaiz⁶ · Salvatore Gallone² · Maurizio Grassano¹ · Umberto Manera¹,² · Marco Pagani³,⁷ · Adriano Chiò¹,²,³,⁴

Received: 25 July 2021 / Accepted: 20 December 2021 / Published online: 25 January 2022 © The Author(s) 2022

Abstract

Purpose Neuropathological data suggest that ALS with SOD1 mutations (SOD1-ALS) is a distinct form of ALS. We evaluated brain metabolic changes characterizing SOD1-ALS as compared to sporadic ALS (sALS), employing ¹⁸F-fluorodeoxyglucose-positron-emission tomography (¹⁸F-FDG-PET).

Methods We included 18 SOD1-ALS patients, 40 healthy controls (HC), and 46 sALS patients without mutations in SOD1, TARDBP, FUS, and C9ORF72, randomly selected from 665 subjects who underwent brain ¹⁸F-FDG-PET at diagnosis between 2008 and 2019 at the ALS Centre of Turin. We excluded patients with frontotemporal dementia. We used the full factorial design in SPM12 to evaluate whether differences among groups exist overall. In case the hypothesis was confirmed, group comparisons were performed through the two-sample t-test model of SPM12. In all the analyses, the height threshold was P < 0.001 (P < 0.05 FWE-corrected at cluster level).

Results The full factorial design resulted in a significant main effect of groups. We identified a relative hypometabolism in sALS patients compared to SOD1-ALS cases in the right precentral and medial frontal gyrus, right paracentral lobule, and bilateral postcentral gyrus. SOD1 patients showed a relative hypermetabolism as compared to HC in the right precentral gyrus and paracentral lobule. As compared to HC, sALS patients showed relative hypometabolism in frontal, temporal, and occipital cortices.

Conclusion SOD1-ALS was characterized by a relative hypermetabolism in the motor cortex as compared to sALS and HC. Since promising, targeted, therapeutic strategies are upcoming for SOD1-ALS, our data support the use of PET to study disease pathogenesis and to track its course in clinical trials, in both asymptomatic and symptomatic mutation carriers.

Keywords Amyotrophic lateral sclerosis (ALS) · SOD1 · ¹⁸F-FDG-PET · Brain metabolism · Marco Pagani and Adriano Chiò equally contributed to this work.

This article is part of the Topical Collection on Neurology.
**Introduction**

Amyotrophic lateral sclerosis is characterized by the progressive degeneration of upper and lower motor neurons, leading to voluntary muscle wasting and weakness, and causing death within 2–5 years from onset [1]. Approximately 10% of cases are familial (fALS), while 90% are thought to be sporadic (sALS) [2]. SOD1 mutations were identified as a cause of fALS in 1993 [3]. Afterwards, they were detected also in ~1% of sALS cases [2]. SOD1-ALS seems to be a distinct form of ALS, since the neuropathological hallmark in ~95% of ALS cases is the cytoplasmic mislocalization and aggregation of hyperphosphorylated TDP-43 (pTDP-43) within neurons and glia, while in SOD1-ALS, no pTDP43 staining is detected in the motor cortex [4]. The study of the peculiarities of the neurodegenerative cascade in SOD1-ALS has led to the promising development of an antisense oligonucleotide that mediates the degradation of SOD1 messenger RNA to reduce SOD1 protein synthesis [5]. Brain 18F-fluorodeoxyglucose-positron-emission tomography (18F-FDG-PET) is a powerful tool to investigate the involvement of brain structures and functions in ALS in vivo [6], and is a potentially useful biomarker for the assessment of the extent of brain lesions [7]. Recent works have demonstrated that 18F-FDG-PET is able to disclose the metabolic brain correlates of different aspects of ALS phenotype, including the extent of motor deficits [8], and the presence of cognitive [9] and behavioral impairment [10]. A number of studies [11, 12] highlighted the metabolic features which characterize patients carrying the C9ORF72 expansion. Otherwise, 18F-FDG-PET investigations focused on SOD1 mutation carriers are still lacking. Therefore, the aim of the present study was the identification of brain metabolic changes characterizing SOD1-ALS as compared to sALS, employing 18F-FDG-PET.

**Materials and methods**

**Study participants**

We included 18 patients carrying SOD1 mutations, diagnosed with genetically determined ALS according to El Escorial revised diagnostic criteria [13] at the ALS Centre of Turin (‘Rita Levi Montalcini’ Department of Neuroscience, University of Turin, Turin, Italy), between 2008 and 2019. A comparison cohort of patients diagnosed with definite, probable, and probable laboratory-supported sALS according to El Escorial revised diagnostic criteria [13] was randomly collected from the series of 665 subjects who underwent brain 18F-FDG-PET at diagnosis in the same time period at the ALS Centre of Turin. The sALS cohort included subjects without mutations in the major ALS-related genes (i.e. SOD1, TARDBP, FUS, C9ORF72). Fifty sALS were originally collected. Then, they were reduced to 46 because we excluded 4 patients with frontotemporal dementia (FTD), since no patients in our SOD1 group had FTD, in agreement with published literature suggesting that dementia is rare in patients carrying mutations of this gene [14, 15]. Since SOD1 patients more often show a flail-leg phenotype with prevalent lower motor neuron involvement as compared to non-carriers [16, 17], we evaluated patients’ motor phenotype in order to explain eventual brain metabolic differences. We applied a modified version of the classification proposed by Pioro and colleagues [17] for phenotypic classification: (1) ALS, if lower motor neuron (LMN) signs (i.e., fasciculations, atrophy, and weakness) and unequivocal upper motor neuron (UMN) signs (i.e., spasticity, Babinski sign, Hoffmann sign, and clonus) were present; (2) ALS with probable UMN signs (ALS-UMN), in the presence of prominent LMN signs with preserved or mild to moderately hyperactive stretch reflexes but without spasticity, extensor plantar responses, Hoffmann sign, or clonus; and (3) pure LMN, where only LMN signs were evident. Furthermore, the King’s stage at PET was obtained for sALS and SOD1 patients from the ALSFRS-R scale fulfilled at the time of PET scan, according to a published algorithm [18].

We included in the analyses 40 healthy controls (HC). We considered eligible as controls subjects referred to the PET Centre for suspected lung cancer (i) with no oncologic disease detected, (ii) with brain PET scan reported as normal by the nuclear medicine physician, (iii) without history of neurological disorders, and (iii) with normal neurological examination.

**Genetic analysis**

All patients underwent genetic analysis for C9ORF72, SOD1, TARDBP, and FUS genes. All the coding exons and 50 bp of the flanking intron-exon boundaries of SOD1, of exon 6 of TARDBP, and of exons 14 and 15 of FUS have been PCR amplified, sequenced using the BigDye Terminator v3.1 sequencing kit (Applied Biosystems Inc.), and run on an ABIPrism 3500 genetic analyzer. These exons were selected as the vast majority of known pathogenic variants are known to lie within these mutational hotspots. A repeat-primed PCR assay was used to screen for the presence of the GGGGCC hexanucleotide expansion in the first intron of C9ORF72. A cut-off of ≥30 repeats was considered pathological [19].
Brain $^{18}$F-FDG-PET was performed according to published guidelines [20]. Patients fasted at least 6 h before the exam. Blood glucose was <7.2 mmol/l in all cases before the procedure. After a 20-min rest, about 185 MBq of $^{18}$F-FDG was injected. The acquisition started 60 min after the injection. In the patient group, a whole-body scan was performed setting head-first. In the control group, a separate brain scan was performed after the whole-body one with a time difference of 15 min. The $^{18}$F-FDG-PET acquisition procedure was performed in the same environmental conditions in patients and controls, according to published guidelines [20]. PET/CT scans were performed on a Discovery ST-E System (General Electric). Brain CT (slice thickness of 3.75 mm, 140 kV, 60–80 mAs), and PET scan was sequentially acquired, the former being used for attenuation correction of PET data. The PET images were reconstructed with 4 iterations and 28 subsets with an initial voxel size of 2.34 × 2.34 × 2.00 mm, and data were collected in 128 × 128 matrices.

### Statistical analysis

The demographic and clinical characteristics of patient groups ($SOD1$ patients and sALS patients) and HC were compared as follows. The $\chi^2$-test was employed for categorical variables. The Mann-Whitney test was used for quantitative, continuous variables.

SPM12 implemented in Matlab R2018b (MathWorks, Natick, MA, USA) was used for image spatial normalization to a customized brain $^{18}$F-FDG-PET template [21]. Normalization with a subcortical reference region was not considered as an option, since all brain regions have been demonstrated to be potentially affected in ALS. Intensity normalization was performed using the 0.8 default SPM value of grey matter threshold, and images were smoothed with a 10-mm filter and submitted to statistical analysis.

Although the scope of the study was the assessment of metabolic differences between sALS and $SOD1$-related ALS, for a more exhaustive characterization of patient metabolic state, we also included HC in the analyses.

We used the full factorial design as implemented in SPM12 to test the hypothesis that differences among groups ($SOD1$, sALS, HC) exist overall (i.e., main effect of groups). Age at PET and sex were used as covariates, and the height threshold was set at $P < 0.001$ ($P < 0.05$ FWE-corrected at cluster level). In all the analyses, only clusters containing >125 contiguous voxels were considered significant. Brodmann areas (BAs) were identified at a 0–2-mm range from the Talairach coordinates of the SPM output isocentres corrected by Talairach Client (http://www.talairach.org/index.html).

### Results

#### Demographic, clinical, and genetic data

The comparison of demographic and clinical data of $SOD1$-patients and sALS cases is reported in Table 1. We found significant differences between $SOD1$-patients and sALS subjects for site of onset and motor phenotype. Bulbar onset was less frequent in the $SOD1$ group, in agreement with population-based data from Italy [16]; the pure LMN phenotype was present only in the $SOD1$-ALS, in agreement with the published literature reporting that such phenotypic variant is frequent among $SOD1$ mutations carriers [15, 16].

|                      | sALS     | $SOD1$-ALS |
|----------------------|----------|------------|
| N (IQR)              | 46 (40.0–43.0) | 18 (15–21) |
| Sex                  |          |            |
| Male                 | 19 (41.3)  | 7 (38.9)   |
| Female               | 27 (58.7)  | 11 (61.1)  |
| Site of onset        |          |            |
| Bulbar onset         | 19 (41.3)  | 1 (5.6)    |
| Spinal onset         | 27 (58.7)  | 17 (94.4)  |
| Motor phenotype      |          |            |
| Pure LMN             | 0 (0.0)   | 4 (22.2)   |
| ALS-PUMNS            | 24 (52.2)  | 5 (27.8)   |
| ALS                  | 22 (47.8)  | 9 (50.0)   |
| King’s staging       |          |            |
| Stage 1              | 13 (28.3)  | 6 (33.3)   |
| Stage 2              | 14 (30.4)  | 5 (27.8)   |
| Stage 3              | 16 (34.8)  | 7 (38.9)   |
| Stage 4a/4b          | 3 (6.5)    | 0 (0.0)    |

|                      | sALS     | $SOD1$-ALS |
|----------------------|----------|------------|
| Age at PET (years)   | 65.4 (58.2–74.5) | 62.2 (57.1–69.0) |
| ALSFRS-R total score| 40.0 (33.7–43.0) | 38.0 (35.7–40.2) |

Comparison of demographic and clinical characteristics of sALS and $SOD1$-ALS patients. Significant differences are reported in bold. ALSFRS-R: ALS Functional Rating Scale – Revised. Pure LMN: pure lower motor neuron phenotype. ALS-PUMNS: ALS with probable Upper Motor Neuron signs.
median age at PET of HC (66.5 years, IQR 57.1–69.0) did not result significantly different from SOD1 (P = 0.346) and sALS patients (P = 0.372). In the control group, 29 subjects were male (72.5%) and 11 female (27.5%). Sex distribution resulted different as compared to SOD1 (P = 0.015) and sALS subjects (P = 0.004). The effect of site of onset and sex on the results was kept under control including them as covariates in the analyses.

Among SOD1 patients, four carried the p.Gly94Asp (c.281G > A) mutation, three the p.Leu145Phe (c.435G > C), and two the p. Asp110Tyr (c.328G > T). The following 9 mutations were found in one patient each: p.Gly148Cys (c.442G > T), p.Gly42Ser (c.124G > A), p.Leu85Phe (c.255G > C), p.Asn66Thr (c.197A > T), p.Ser108LeufsTer15 (c.320_321insT), p.Gly73Ser (c.217G > A), p.Asn20Ser (c.59A > G), p.Val6Met (c.16G > A), and p.Asn66Ser (c.197A > G).

18F-FDG-PET data

Full factorial analysis

The full factorial design resulted in a significant main effect of groups (Supplemental Figure 1) in clusters mainly including frontal and occipital regions. We hence computed the post hoc comparisons among the three groups.

SOD1-ALS vs sALS

We identified a relative hypometabolism in the sALS group compared to the SOD1 group in a cluster including the right precentral and medial frontal gyrus, the right paracentral lobule, and bilateral postcentral gyrus (Figure 1; Table 2). We did not identify any cluster of relative hypermetabolism in sALS patients as compared to SOD1 patients.

SOD1-ALS vs HC

We did not find any cluster of relative hypometabolism in the SOD1 group as compared to HC. SOD1 patients showed a cluster of relative hypermetabolism as compared to HC, including the right precentral gyrus and paracentral lobule (Figure 2; Table 3).

sALS vs HC

As compared to HC, sALS patients showed large clusters of relative hypometabolism, mainly in frontal, temporal, and occipital cortices (Figure 3; Table 4). We did not find any cluster of relative hypermetabolism in sALS patients as compared to HC.

Discussion

In the present study, we evaluated the brain metabolic hallmarks of SOD1-ALS as compared to sporadic ALS. In the direct comparison between SOD1 and sALS patients, sALS subjects showed a relative hypometabolism in motor regions. Strikingly, in the comparison of each group with HC, the same motor areas resulted to be relatively hypometabolic in the sALS group and relatively hypermetabolic in the SOD1 group.

The clusters of relative hypometabolism of sALS patients as compared to HC were mainly located in the frontal and occipital cortex, in agreement with the results of a previous study comparing ALS patients and healthy controls [22].

The finding of a relative hypometabolism in the motor cortex in sALS patients as compared to SOD1 subjects might be related to the phenotypic differences between the two groups. Indeed, upper motor neuron signs were detected more frequently in the sALS group, while SOD1 patients showed a prevalence of lower motor neuron signs in half of cases. This phenotypic heterogeneity between the two groups is in line with published population-based studies reporting that SOD1-ALS is usually associated with a prevalent lower motor neuron, flail leg picture [15, 16]. Indeed, neuropathological studies report that motor cortex burden is less severe in SOD1-ALS than that observed in sporadic patients with TDP-43 proteinopathy [4]. A recent MRI study
did not identify any difference in cortical thickness between SOD1-ALS patients and sALS subjects [23]. Nevertheless, cortical metabolic changes detected by 18F-FDG-PET may precede gray matter atrophy identified by structural MRI, and therefore may be identified earlier along the disease course [24]. Indeed, a PET study comparing sALS cases and patients who were homozygous for the p.D91A SOD1 mutation showed a relative reduction in cortical 11C-flumazenil binding in the motor and motor association regions of sALS patients, possibly due to the loss of neurons bearing the GABA-A receptors [25]. In order to evaluate whether the metabolic differences between SOD1 and sALS patients were entirely explainable based on the different clinical involvement of upper motor neuron, we repeated the analysis including the motor phenotype among covariates. The results were unchanged (data not shown). Such findings suggest that the metabolic changes that we still observe are due to a different involvement of motor cortical regions between the two groups, that goes beyond the different clinical phenotype. The interpretation of the relative hypermetabolism of the motor cortex in SOD1 cases as compared to HC is more challenging. A recent PET study including asymptomatic

| Table 2 | Clusters showing a statistically significant relative hypometabolism in the sALS group as compared to the SOD1 group (BA = Brodmann area) |
|---------|----------------------------------------------------------------------------------|
| p(FWE-corrected) | Cluster extent | Z-score | Talairach coordinates | Lobe | Cortical region | BA |
| 0.000   | 1473          | 4.09    | 4 -34 68               | Frontal | Right paracentral lobule | 4 |
| 3.74    | 32            | 22 71   | Frontal Right precentral gyrus | 4 |
| 3.69    | -4 53 71      | Parietal Left postcentral gyrus | 7 |
| 3.54    | 2 -49 69      | Parietal Right postcentral gyrus | 7 |
| 3.47    | 8 -15 50      | Frontal Right medial frontal gyrus | 6 |

| Fig. 2 | SOD1 group versus HC. |
|--------|-----------------------|
| The regions showing a statistically significant relative hypermetabolism in SOD1 patients as compared to HC are marked in green and are reported on axial sections of a brain magnetic resonance imaging template and on the brain surface of a glass brain rendering (bottom right) |

| Table 3 | Clusters showing a statistically significant relative hypermetabolism in the SOD1 group as compared to healthy controls (BA = Brodmann area) |
|---------|----------------------------------------------------------------------------------|
| p(FWE-corrected) | Cluster extent | Z-score | Talairach coordinates | Lobe | Cortical region | BA |
| 0.000   | 1094          | 4.74    | 26 -42 56             | Parietal | Right sub-gyral gray matter | 40 |
| 3.84    | 26 -24 69     | Frontal | Right precentral gyrus | 4 |
| 3.70    | 8 -25 49      | Frontal | Right paracentral lobule | 6 |
| 3.68    | 10 -32 50     | Frontal | Right paracentral lobule | 5 |
SOD1 mutations carriers and SOD1-ALS patients reported an increased uptake of a tracer of microglia activation (11C-PK11195) in the motor cortex in symptomatic subjects [26]. 18F-FDG-PET was not performed in that study, but the authors hypothesized that microglial activation, together with astrocyte reaction, might be a phenomenon underlying the finding of glucose hypermetabolism, that has been extensively reported in ALS. This hypothesis is in line with data based on animal models of cerebral ischemia, showing that microglial activation, evidenced by an increased 11C-PK11195 uptake, is associated with increased 18F-FDG uptake [27]. Otherwise, brain double tracer PET studies employing both 11C-PK11195 and 18F-FDG in mild cognitive impairment and early onset Alzheimer’s disease showed microglial activation overlapping clusters of hypometabolism, suggesting a detrimental contribution of microglia in neuron degeneration [28, 29]. A recent study including subjects with mild cognitive impairment showed that higher tau-PET uptake was associated with higher glucose metabolism in patients with lower levels of amyloid-PET uptake. This finding resulted to be associated with lower memory performance [30]. A study focused on the identification of a brain 18F-FDG-PET Parkinson’s disease–related pattern (PDRP) showed that the typical PDRP topography was characterized by relative hypermetabolism in the thalamus, putamen/pallidum, pons, cerebellum, and motor cortex. These changes co-varied with relatively decreased metabolism in the prefrontal, parietal, temporal, and occipital cortices. The topography of metabolic alterations was interpreted as reflecting changes in corticostriatopallidothalamocortical circuits and related pathways in Parkinson’s disease [31]. 18F-FDG-PET hypermetabolism was reported also in Prion disease, situated in many subcortical regions, especially those in limbic and mesolimbic systems. Such findings were interpreted as possibly related to microglial activation, since there is some evidence for microglial activation in Creutzfeldt-Jakob disease [32]. Compiling these data into a coherent framework is challenging. Indeed, the role of microglia in ALS can be ambivalent. Data from the SOD1 transgenic mouse suggest that it can be protective in the early phases and detrimental with the progression of the disease [33]. The importance of its involvement is further supported by studies based on genetic manipulation of mouse models and showing that mutant SOD1 must be expressed in microglia and astrocytes, in addition to motor neurons, to produce the ALS-like phenotype [34].

Our study has some limitations. First, the relatively small size of the SOD1 group might have influenced our findings. Nevertheless, almost all published neuroimaging studies including SOD1-ALS patients have a smaller sample size than the present study, and none of them employed brain 18F-FDG-PET [35]. Second, we included patients carrying different SOD1 mutations. Nevertheless, neuropathological data point to SOD1-ALS as a relatively homogenous entity.
Third, we could not perform partial volume effect correction for cortical atrophy, since brain MRI was not available for all patients. However, according to previous studies, including voxel-based atrophy correction of resting glucose metabolism, metabolic measurement resulted to be relatively independent of cortical atrophy [36].

The recent European Academy of Nuclear Medicine and European Academy of Neurology recommendations about the use of brain $^{18}$F-FDG-PET did not suggest its clinical use in ALS. Accordingly, our data support its application in a research setting, including clinical trials [37]. We found that $SOD1$-ALS was characterized by a relatively higher metabolism in the motor cortex as compared to sporadic ALS and healthy controls. Since promising, targeted, therapeutic strategies are upcoming for $SOD1$-ALS [5], the study of the neurodegenerative process associated with this genetic form of ALS through PET imaging can provide potentially useful biomarkers to understand disease pathogenesis and to track the disease course in clinical trials, in both asymptomatic and symptomatic mutation carriers.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00259-021-05668-7.

**Availability of data and material** Data are available from the authors upon reasonable request.

**Author contribution** Study concept and design: Antonio Canosa, Marco Pagani, Adriano Chiò.

Acquisition of data: Antonio Canosa, Andrea Calvo, Cristina Moglia, Rosario Vasta, Francesca Palumbo, Luca Solero, Francesca Di Pede, Sara Cabras, Vincenzo Arena, Grazia Zocco, Federico Casale, Maura Brunetti, Luca Sbaiz, Salvatore Gallone, Maurizio Grassano, Umberto Manera.
Analysis and interpretation of data: Antonio Canosa, Marco Pagani, Adriano Chiò.

Drafting of the manuscript: Antonio Canosa, Marco Pagani, Adriano Chiò.

Critical revision of the manuscript for important intellectual content: Andrea Calvo, Cristina Moglia, Rosario Vasta, Francesca Palumbo, Luca Solero, Francesca Di Pede, Sara Cabras, Vincenzo Arena, Grazia Zoccoli, Federico Casale, Maura Brunetti, Luca Sbaiz, Salvatore Gallone, Maurizio Grassano, Umberto Manera.

Obtained funding: Marco Pagani, Adriano Chiò.

Administrative, technical and material support: Andrea Calvo, Cristina Moglia, Rosario Vasta, Francesca Palumbo, Luca Solero, Francesca Di Pede, Sara Cabras, Vincenzo Arena, Grazia Zoccoli, Federico Casale, Maura Brunetti, Luca Sbaiz, Salvatore Gallone, Maurizio Grassano, Umberto Manera.

Study supervision: Antonio Canosa, Marco Pagani, Adriano Chiò.

Antonio Canosa had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors have approved the submitted version of the article. The information reported in the manuscript has never been reported elsewhere.

Funding This work was in part supported by a grant from the Thierry Latran Foundation (INSPIRE project), the Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata, grant RF-2016-02362405), the European Commission’s Health Seventh Framework Programme (FP7/2007-2013 under grant agreement 259867), the Joint Programme - Neurodegenerative Disease Research (Strength, ALS-Care and Brain-Mend projects), granted by the Italian Ministry of Education, University and Research, and the Progetti di Rilevante Interesse Nazionale (PRIN) 2017 granted by the Italian Ministry of Education, University and Research (grant 2017SNW5MB). This study was performed under the Department of Excellence grant of the Italian Ministry of Education, University and Research to the ‘Rita Levi Montalcini’ Department of Neuroscience, University of Turin, Italy.

Declarations

Disclaimer The sponsor organizations had no role in data collection and analysis and did not participate to writing and approving the manuscript. Funding sources had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Ethical approvals and patient consents The study was approved by the ethical committee ‘Comitato Etico Interaziendale Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino.’ The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. All of the patients signed written informed consent. They did not receive any remuneration for participation.

Competing interests Antonio Canosa, Cristina Moglia, Rosario Vasta, Francesca Palumbo, Luca Solero, Francesca Di Pede, Sara Cabras, Vincenzo Arena, Grazia Zoccoli, Federico Casale, Maura Brunetti, Luca Sbaiz, Salvatore Gallone, Maurizio Grassano, Umberto Manera, Marco Pagani: no disclosures.

Andrea Calvo has received a research grant from Cytokinetics. Adriano Chiò serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Cytokinetics, Denali Therapeutics, Amylyx, and AveXis.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. van ES MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet Lond Engl. 2017;390(10107):2084–98.
2. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17–23.
3. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59–62.
4. Nolan M, Scott C, Gamarallage MP, Lunn D, Carpenter K, McDonough E, et al. Quantitative patterns of motor cortex proteinopathy across ALS genotypes. Acta Neuropathol Commun. 2020;8(1):98.
5. Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1–2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2).
6. Chio A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol. 2014;13(12):1228–40.
7. Kassubek J, Pagani M. Imaging in amyotrophic lateral sclerosis: MRI and PET. Curr Opin Neurol. 2019;32(5):740–6.
8. Canosa A, Calvo A, Moglia C, Manera U, Vasta R, Di Pede F, et al. Brain metabolic changes across King’s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-position emission tomography study. Eur J Nucl Med Mol Imaging. 2021;48(4):1124–33.
9. Canosa A, Moglia C, Manera U, Vasta R, Torriceri MC, Arena V, et al. Metabolic brain changes across different levels of cognitive impairment in ALS: a 18 F-FDG-PET study. J Neurol Neurosurg Psychiatry. 2020;91(5):328.
10. Canosa A, Vacchiano V, D’Ovidio F, Calvo A, Moglia C, Manera U, et al. Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18F-FDG-positron emission tomography study. J Neurol. 2021;28(3):745–53.
11. Cistaro A, Pagani M, Montuschi A, Calvo A, Moglia C, Canosa A, et al. The metabolic signature of C90RF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging. 2014;41(5):844–52.
12. Van Laere K, Vanhee A, Verschuuren J, De Coster L, Driesen A, Dupont P, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71(5):553–61.
13. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler Other Motor Neuron Disord. 2000;1:5.
14. Wicks P, Abrahams S, Papps B, Al-Chalabi A, Shaw CE, Leigh PN, et al. SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J Neurol. 2009 Feb;256(2):234–41.
15. Shatunov A, Al-Chalabi A. The genetic architecture of ALS. Neurobiol Dis. 2021;147:105156.
16. Chiò A, Moglia C, Canosa A, Manera U, D’Ovidio F, Vasta R, et al. ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology. 2020;94(8):e802–10.
17. Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology. 1994;44(10):1933–3.
18. Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Front Degener. 2014;15(3–4):279–84.
19. Renton AE, Majoumie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs IR, et al. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2).
20. Varrone A, Asenbaum S, Vander Borch T, Booij J, Nobili F, Nägren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36(12):2103–10.
21. Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12(4):575–93.
22. Pagani M, Chio A, Valentini MC, Oberg J, Nobili F, Calvo A, Pagani M, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83(12):1067–74.
23. Agosta F, Spinelli EG, Marjanovic IV, Stevic Z, Pagani E, Valvasisa P, et al. Unraveling ALS due to SOD1 mutation through the combination of brain and cervical cord MRI. Neurology. 2018;90(8):e707–16.
24. Rajagopalan V, Pioro EP. Comparing brain structural MRI and metabolic FDG-PET changes in patients with ALS-FTD: ‘the chicken or the egg?’ question. J Neurol Neurosurg Psychiatry. 2015;86(9):952–8.
25. Turner MR. Abnormal cortical excitability in sporadic but not homoygous D90A SOD1 ALS. J Neurol Neurosurg Psychiatry. 2005;76(9):1279–85.
26. Tondo G, Iaccarino L, Cerami C, Vanoli GE, Presotto L, Masiello V, et al. C-PK11195 PET–based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(9):1513–23.
27. Schroeter M, Dentiin MA, Walberer M, Backes H, Neumaier B, Fink GR, et al. Neuroinflammation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [11C]PK11195- and [18F] FDG-PET study. J Cereb Blood Flow Metab. 2009;29(6):1216–25.
28. Tondo G, Boccalini C, Caminiti SP, Presotto L, Filippi M, Magnani G, et al. Brain metabolism and microglia activation in mild cognitive impairment: a combined [18F]FDG and [11C]-(R)-PK11195 PET study. J Alzheimers Dis. 2021;80(1):433–45.
29. Tondo G, Iaccarino L, Caminiti SP, Presotto L, Santangelo R, Ianaccone S, et al. The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease. Alzheimers Res Ther. 2020;12(1):50.
30. Rubinski A, Franzemeier N, Neitzel J, Ewers M. Alzheimer’s disease neuroimaging initiative (ADNI). FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels. Alzheimers Res Ther. 2020;12(1):133.
31. Meles SK, Renken RJ, Pagani M, Teune LK, Arnaldi D, Morbelli S, et al. Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts. Eur J Nucl Med Mol Imaging. 2020;47(2):437–50.
32. Mente KP, O’Donnell JK, Jones SE, Cohen ML, Thompson NR, Bizzi A, et al. Fluorodeoxyglucose positron emission tomography (FDG-PET) correlation of histopathology and MRI in Prion disease. Alzheimer Dis Assoc Disord. 2017;31(1):1–7.
33. Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31(5):635–9.
34. Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211–20.
35. Hääkkinen S, Chu SA, Lee SE. Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol Dis. 2020;145:105063.
36. Ibanez L, Dube U, Davis AA, Fernandez MV, Budde J, Cooper B, et al. Pleiotropic effects of variants in dementia genes in Parkinson disease. Front Neurosci. 2018;12(12):230.
37. Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nester P, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25(10):1201–17.

The information reported in the manuscript has never been reported elsewhere.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.